Fragment-based screening of the bromodomain of ATAD2.
Authors
Harner
MJ
Mary J
,
Chauder
BA
Brian A
,
Phan
J
Jason
,
Fesik
SW
Stephen W
.
Journal of medicinal chemistry. 2014 11 26; 57(22).
9687-92
Journal of medicinal chemistry. 2014 11 26; 57(22).
9687-92
Abstract
Cellular and genetic evidence suggest that inhibition of ATAD2 could be a useful strategy to treat several types of cancer. To discover small-molecule inhibitors of the bromodomain of ATAD2, we used a fragment-based approach. Fragment hits were identified using NMR spectroscopy, and ATAD2 was crystallized with three of the hits identified in the fragment screen.